Biocon launches Bosanya and Aukelso biosimilars, expanding affordable osteoporosis and cancer bone therapies for patients.

• Bosanya (60 mg/mL) treats postmenopausal osteoporosis, glucocorticoid‑induced loss; Aukelso (120 mg) prevents skeletal events in multiple myeloma
• Both products received provisional interchangeability, allowing pharmacy‑level substitution under state regulations for greater patient access
• Denosumab US sales hit $5 billion in 2024; Biocon aims to provide cheaper alternatives for patients